Clinical trials: Neoplasms, Solid Tumor
Mesothelioma, Epithelioid Hemangioendothelioma(EHE)
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in…
- Conditions
- Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
- Trial name
- NCT06452160
- Testing
- BGC515
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- BridGene Biosciences Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI315, a HER2/PD-1 bi-specific antibody in patients with advanced solid tumors
- Trial name
- NCT04162327
- Testing
- IBI315
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neoplasms
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
- Trial name
- NCT00547261
- Testing
- SSR97225
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Refractory Solid Tumors, Next Generation Sequencing
MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors
The MyCustom study is a investigator initiated trial(IIT), prospective real-world clinical research project, a genetic biomarker-driven "basket" (tissue-type agonistic) study.
- Trial name
- NCT06030869
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Second Hospital
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Depression, Neurotoxicity
Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease…
- Conditions
- Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00069927
- Testing
- Adderall-XR®, Concerta®
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Advanced/Metastatic Solid Tumors
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
- Trial name
- NCT03833427
- Testing
- Selumetinib, Pembrolizumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
Unspecified Childhood Solid Tumor, Protocol Specific
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
Phase I trial to study the effectiveness of irofulven in treating children with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells so they stop growing or die.
- Trial name
- NCT00003370
- Testing
- irofulven
- Where
- 56 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Horton's Disease, Infectious Disease
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease.
- Conditions
- Horton's Disease, Infectious Disease, Neoplasia, Solid Tumor
- Trial name
- NCT02065297
- Testing
- 1 blood sample, 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
- Where
- 3 sites in France
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Advanced Solid Tumors
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.
- Trial name
- NCT04261075
- Testing
- IPH5201, durvalumab, oleclumab
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 57 people
- Sponsor
- MedImmune LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural
- Trial name
- NCT05278975
- Testing
- RSO-021
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- RS Oncology LLC
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Advanced Solid Tumor
A Study of HS-10342 in Patients With Advanced Solid Tumor
HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of HS-10342 in Chinese advanced solid tumor patients.
- Trial name
- NCT04060511
- Testing
- HS-10342
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumors
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
the main purpose: Evaluate the safety and resistance of BAT6026 injection as a single agent in the treatment of patients with locally advanced or metastatic solid tumors Acceptability Explore maximum tolerated dose (MTD) or…
- Trial name
- NCT05105971
- Testing
- BAT6026
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Bio-Thera Solutions
Advanced KRAS G12D Mutant Solid Tumors
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors.
- Trial name
- NCT07134998
- Testing
- HRS-6093
- Where
- 2 sites in China
- Volunteers
- 153 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignant Tumors
A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.
- Trial name
- NCT07032298
- Testing
- SSGJ-612
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Cancer, COVID
The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients
Since December 2019, China and then the rest of the world have been affected by the rapid development of a new coronavirus, SARS-CoV-2 (severe acute respiratory syndrome corona virus 2).
- Conditions
- Cancer, COVID, Solid Tumor, Social Inequality
- Trial name
- CACOVID-19 (NCT04397575)
- Where
- 148 sites in France
- Volunteers
- 1,523 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.